Effect and safety of immunotherapy among elder patients (age >/= 65) with recurrent or metastatic nasopharyngeal carcinoma. Xie RL, Cai WL, Ouyang YF, Zou YH, et al. BMC Cancer 2025;25:691.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xie RL, Cai WL, Ouyang YF, Zou YH, et al. Effect and safety of immunotherapy among elder patients (age >/= 65) with recurrent or metastatic nasopharyngeal carcinoma. BMC Cancer 2025;25:691.
PMID: 40229737